Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Innovent Announces the Approval of Pemazyre® (pemigatinib) in Taiwan, China Market for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a F

prnasiaJune 22, 2021

Tag: Innovent , Pemazyre , Incyte

PharmaSources Customer Service